Abelcet Articles
Italy’s Sigma-Tau to takeover Enzon business for some $327 million in cash plus royalties
10 November 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
BDSI enters accord with DNDi to assess Bioral Amphotericin B
26 January 2009
Gilead up almost 30% on HIV franchise
27 October 2008
Mycamine has low AEs in premature infants
8 September 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
Gilead record sales push revenue up 22%
28 April 2008
Samaritan gets Amphocil MAA in Cyprus
12 November 2007
Samaritan also to market Amphocil in Ireland
22 October 2007
Merck & Co's Cancidas comparable to AmBisome in IFI
1 October 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
EU orphan status for Nektar's ABIP
25 September 2006
Accentia amends license deal with Mayo
4 September 2006
Japan stock market week to June 19, 2006
26 June 2006
Enzon swings to $286M loss in 4th-qtr 2005
13 March 2006
Gilead reports $2B revenue in 2005, up 53%
6 February 2006
Cephalon makes $360M cash offer for Zeneus
12 December 2005
Gilead's 2nd-qtr revenues up 55%
1 August 2005
Three Rivers buys Amphotec/Amphocil rights
6 June 2005
Fujisawa's 9-month sales rise 2.5%
21 February 2005
Aspirations of Astellas Pharma, the merged Yamanouchi/Fujisawa
22 November 2004
Gilead sees sales jump 30% for 2nd-qtr
9 August 2004
Medeus acquires Elan business for $120M
23 February 2004
Gilead soars on strong HIV drug sales
10 November 2003
Vicuron antifungal promising in Phase II
19 May 2003
Lost revenues hit Elan as losses widen further
12 May 2003
Gilead predicts good Viread sales in 2003
24 March 2003
Sales rocket at Gilead on Viread growth
10 February 2003
Sankyo, Fujisawa in cross-licensing deal
27 January 2003
Benefits of Pfizer's voriconazole shown
12 August 2002
Gilead unveils 1st-qtr net loss of $3.8m
13 May 2002
Fujisawa files for new antifungal in USA
6 May 2002
Pfizer antifungal drug cleared by EMEA
1 April 2002
Strong earnings growth for Ireland's Elan on healthy US sales
11 February 2002
Healthy revenue growth at Gilead
11 February 2002
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Fujisawa sales soar in North America
12 November 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Pfizer's Vfend nears US aproval
8 October 2001
FDA panel recommends Pfizer's Vfend
5 October 2001
Pfizer's Vfend on track for US approval?
4 October 2001
InterMune forecasts larger losses
18 June 2001
Despite revenue rise, Gilead loss increases
1 May 2001
Elan net income leaps 89% in 1st qtr
24 April 2001
Merck & Co gets US approval for new antifungal agent Cancidas
30 January 2001
Elan full-year 2000 sales top $1.50 billion
29 January 2001
US FDA panel backs approval of Merck & Co's antifungal Cancidas
17 January 2001
InterMune buys Alza's Amphotec with upfront payment of $9 mill
11 January 2001
Merck files NDA for new antifungal agent Cancidas
27 September 2000
FDA backs new AmBisome indication
7 July 2000
US 1st-quarter results continue to flow in
3 May 2000
Elan to acquire The Liposome Company
6 March 2000
FDA approves sNDA for AmBisome, superiority over Abelcet
17 February 2000
Fujisawa lifts FY 2000 earnings forecasts
1 November 1999
Aronex' Atragen not approvable, says FDA
27 September 1999
Aronex's Atragen NDA is "insufficient"
6 August 1999
Fujisawa and NeXstar file for AmBisome
15 July 1999
Gilead Sciences to merge with NeXstar
2 March 1999
Amgen Australia to market The Liposome Company's Abelcet
15 October 1998
Nyotran Effective In Resistant Mycoses
13 October 1998
Alza Boosts Oncology With $580M Sequus Acquisition
6 October 1998
New Indication For AmBisome In UK
20 August 1998
The Liposome Co Cutting Its Losses
12 August 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
Mixed Fortunes For US Companies In 1st Qtr
14 May 1998
More US Year-End 1997 Corporate Results
24 February 1998
Hong Kong OK For Liposome's Abelcet
6 February 1998
New Antifungals Highlighted At ICAAC
13 November 1997
3rd Qtr Revenues Up For US Drug & Biotech Firms
6 November 1997
Wyeth-Ayerst To Market TLC's Abelcet In Italy And France
28 August 1997
FDA Approves AmBisome For Empirical Therapy
14 August 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
The Liposome Company: Focusing On Oncology
21 July 1997
Progress With AmBisome In USA
17 July 1997
Liposome Company's ARDS Drug Fails At Ph III
8 July 1997
US Quarterly Financial Results Round-Up
12 May 1997
Amphotec Role Examined In New Studies
24 April 1997
TLC Expects 40% Rise In Abelcet Sales
7 April 1997
US Biopharma Firms See Research Bear Fruit In '96
17 February 1997
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
